<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03871114</url>
  </required_header>
  <id_info>
    <org_study_id>miR-155 OLP</org_study_id>
    <nct_id>NCT03871114</nct_id>
  </id_info>
  <brief_title>Evaluation of Salivary Level of miR-155 and IL-10 in Oral Lichen Planus Patients Before and After Treatment With Topical Corticosteroid</brief_title>
  <official_title>Evaluation of Salivary Levels of miR-155 and IL-10 in Oral Lichen Planus Patients Before and After Treatment With Topical Corticosteroid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thirty patients will be recruited from the outpatient clinic of the faculty of
      dentistry.fifteen systemically healthy individuals with normal mucosa and fifteen
      atrophic/erosive oral lichen planus patients. Oral lichen planus patients will be treated
      with a topical steroid and miR-155 and IL-10 will be assessed in saliva before and after 4
      weeks of topical steroids use
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 10, 2019</start_date>
  <completion_date type="Actual">April 25, 2019</completion_date>
  <primary_completion_date type="Actual">April 10, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of salivary levels of miR-155 in OLP before treatment</measure>
    <time_frame>baseline</time_frame>
    <description>assessment of miR-155 in saliva of patients with OLP before treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of salivary levels of IL-10 in OLP before treatment</measure>
    <time_frame>baseline</time_frame>
    <description>assessment of IL-10 in saliva of patients with OLP before treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of salivary levels of miR-155 in OLP after treatment</measure>
    <time_frame>4 weeks</time_frame>
    <description>assessment of miR-155 in saliva of patients with OLP after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of salivary levels of IL-10 in OLP after treatment</measure>
    <time_frame>4 weeks</time_frame>
    <description>assessment of IL-10 in saliva of patients with OLP after treatment</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Oral Lichen Planus</condition>
  <arm_group>
    <arm_group_label>OLP patients</arm_group_label>
    <description>fifteen patients with atrophic /erosive OLP will receive treatment with topical triamcinolone acetonide in orabase 1mg/g 3 times /day and assessed every week for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide in orabase</intervention_name>
    <description>treatment of OLP with topical steroid</description>
    <arm_group_label>OLP patients</arm_group_label>
    <other_name>topical corticosteroid</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with atrophic/erosive oral lichen planus
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients clinically and histopathologically diagnosed as having atrophic/erosive OLP.

          -  Patients free from any other oral lesions

          -  cooperative patients who agrees to take the supplied medications.

          -  Patients who are systemically healthy

        Exclusion Criteria:

          -  Patients suffering from any systemic disease.

          -  Treatment with any systemic treatment such as systemic steroids, other
             immunosuppressive drugs or non-steroidal anti-inflammatory drugs at least eight weeks.

          -  Treatment with any oral topical medications for at least four weeks prior to the
             study.

          -  Pregnant and lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Dentistry</name>
      <address>
        <city>Cairo</city>
        <zip>11431</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 9, 2019</study_first_submitted>
  <study_first_submitted_qc>March 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Eman Mohamed Amr</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lichen Planus, Oral</mesh_term>
    <mesh_term>Lichen Planus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

